Literature DB >> 6147412

Bromazepam, a new anxiolytic: a comparative study with diazepam in general practice. Royal College of General Practitioners Medicines Surveillance Organisation.

.   

Abstract

In a double-blind randomized trial, 120 patients suffering from acute anxiety states received treatment for two weeks with bromazepam 3 mg, bromazepam 6 mg or diazepam 5 mg, each given three times daily. A shortened Hamilton anxiety rating scale showed similar and significant improvement with all three regimens. However, a global rating scale showed that, in the physicians' opinion, the lower dose of bromazepam was preferred. Its use was associated with the lowest incidence of adverse reactions and best dosage compliance. A twice daily administration of bromazepam may offer further advantage, as may a lower unit dose.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6147412      PMCID: PMC1959670     

Source DB:  PubMed          Journal:  J R Coll Gen Pract        ISSN: 0035-8797


  6 in total

1.  Biopharmaceutical and clinical pharmacokinetic profile of bromazepam.

Authors:  S A Kaplan; M L Jack; R E Weinfeld; W Glover; L Weissman; S Cotler
Journal:  J Pharmacokinet Biopharm       Date:  1976-02

2.  [Clinical trial in double blind at different dosing with valium (author's transl)].

Authors:  C Cherpillod; F Hitz
Journal:  Schweiz Rundsch Med Prax       Date:  1976-06-01

3.  Metabolites of bromazepam, a benzodiazepine, in the human, dog, rat, and mouse.

Authors:  M A Schwartz; E Postma; S J Kolis; A S Leon
Journal:  J Pharm Sci       Date:  1973-11       Impact factor: 3.534

4.  [A new benzodiazepine screened in a parallel double-blind test].

Authors:  F Lens
Journal:  Acta Psychiatr Belg       Date:  1974-05

5.  [Pharmacokinetics of bromazepam in man].

Authors:  J Raaflaub; J Speiser-Courvoisier
Journal:  Arzneimittelforschung       Date:  1974-11

6.  A comparison between bromazepam (Ro 5-3350, Lexotan) and diazepam (Valium) in anxiety neurosis. A controlled, double-blind clinical trial.

Authors:  L M Sonne; P Holm
Journal:  Int Pharmacopsychiatry       Date:  1975
  6 in total
  2 in total

1.  Synthesis and Pharmacological Valorization of Derivatives of 4-Phenyl-1,5-Benzodiazepin-2-One.

Authors:  Terence Nguema Ongone; Redouane Achour; Mostafa El Ghoul; Latifa El Ouasif; Khalid Taghzouti; Meryem El Jemli; Yahia Cherrah; Katim Alaoui; Amina Zellou
Journal:  Adv Pharmacol Sci       Date:  2018-04-01

2.  Prediction of a Therapeutic Dose for Buagafuran, a Potent Anxiolytic Agent by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Starting from Pharmacokinetics in Rats and Human.

Authors:  Fen Yang; Baolian Wang; Zhihao Liu; Xuejun Xia; Weijun Wang; Dali Yin; Li Sheng; Yan Li
Journal:  Front Pharmacol       Date:  2017-10-10       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.